Antisense Pharma Completes Round of Financing Worth Approximately 8 Million Euro
Founding Shareholders Facilitate the Participation of New Investors
Antisense Pharma announced that MIG Funds 2, 3 and 9 as well as GAF have increased their share capital by approximately 8 million euro. In addition, the current Chief Execute Officer (CEO), Dr. Karl-Hermann Schlingensiepen changed from the operative management of Antisense Pharma to a strategic advisory position closely associated with the company as of July 1. Dr. Karl-Hermann Schlingensiepen and the investors developed this solution together.
Until the CEO successor is named, Dr. Hubert Heinrichs, Managing Director and Chief Medical Officer of Antisense Pharma, will assume the position as Acting CEO. Dr. Heinrichs was intensively involved in the current round of financing and he has the investors’ full confidence for the management of all commercial and scientific areas of the company in a competent and target-oriented manner. Dr. Heinrichs, the entire team of Antisense Pharma and administrative board of directors all express their sincere thanks to Dr. Karl-Hermann Schlingensiepen for his excellent performance and dedication to the company.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

New test to make gene therapy safer - SAGA detects tumour potential of viral vectors for blood stem cells
Sartorius establishes Scientific Advisory Board
